While our studies focused on CKM and anti-PD-L1 as vaccine co-treatments, we would expect that our vaccine combined with alternate immune checkpoint inhibitors [38,39] or conditioning agents (i.e., vascular normalizing agents, STING agonists, regulatory cell antagonists, amongst others) [40,41,42,43] that promote inflammation/IFN production in the TME would also yield enhanced anti-tumor efficacy when compared to component monotherapies. The gene discussed is IFNA1; the disease is neoplasm.